Tag: GlobeNewswire

Stockholm, 1st of October 2026 – Virtune today announces the completion of the monthly rebalancing for the Virtune Crypto Top 10 Index ETP, listed on Nasdaq Stockholm for both the SEK-denominated (ISIN code SE0020052207, ticker name VIR10SEK) and the EUR-denominated (ISIN code SE0020052215, ticker name VIR10EUR) ETP.

In addition to the Virtune Crypto Top 10 Index ETP, Virtune’s product portfolio includes:

Virtune Arbitrum ETP
Virtune Avalanche ETP
Virtune Bitcoin ETP
Virtune Bitcoin Prime ETP
Virtune Bittensor ETP
Virtune BNB ETP
Virtune Chainlink ETP
Virtune Coinbase 50 Index ETP
Virtune Crypto Altcoin Index ETP
Virtune Hyperliquid ETP
Virtune Litecoin ETP
Virtune Polygon ETP
Virtune Stablecoin Index ETP
Virtune Staked Cardano ETP
Virtune Staked Ethereum ETP
Virtune Staked NEAR ETP
Virtune Staked Polkadot ETP
Virtune Staked Solana ETP
Virtune Stellar ETP
Virtune Sui ETP
Virtune XRP ETP

Index allocation as of 30th of September (before rebalancing):

Bitcoin: 38.85%
Ethereum: 30.78%
BNB: 9.55%
XRP: 9.12%
Solana: 6.60%
Hyperliquid: 1.83%
Chainlink: 1.06%
Cardano: 0.86%
Stellar: 0.75%
Bitcoin Cash: 0.59%

Index allocation as of 30th of September (after rebalancing):

Bitcoin: 40.00%
Ethereum: 30.56%
BNB: 9.71%
XRP: 8.59%
Solana: 6.36%
Hyperliquid: 1.92%
Chainlink: 0.89%
Cardano: 0.82%
Stellar: 0.67%
Bitcoin Cash: 0.49%

In connection to this month’s rebalancing, there are no changes to the crypto assets included in the index.

The performance of the Virtune Crypto Top 10 Index ETP SEK for September was +9.34%.

The rebalancing is carried out according to the index that the ETP tracks, the Virtune Crypto Top 10 Index. The purpose of the monthly rebalancing is to ensure that the ETP always reflects the current market conditions and to effectively absorb volatility in the crypto market.

Virtune’s crypto index ETP is the first of its kind in the Nordic region. The ETP includes up to 10 leading crypto assets and are based on their total market capitalization, with a maximum weight of 40% per crypto asset to promote diversification. This allows investors to benefit from broad exposure to the crypto market without being heavily concentrated in any single crypto asset.

If you, as an (institutional) investor, are interested in meeting with Virtune to discuss the opportunities our ETPs offer for your asset management services or to learn more about Virtune and our ETPs, please do not hesitate to contact us at hello@virtune.com. You can also read more about Virtune and our ETPs at www.virtune.com and register your email address on our website to subscribe to our newsletters, which cover updates on Virtune’s upcoming ETP launches and other news related to digital assets.

Press contact
Christopher Kock, CEO Virtune AB (Publ)
Christopher@virtune.com
+46 70 073 45 64

Virtune with its headquarters in Stockholm is a regulated Swedish digital asset manager and issuer of crypto exchange traded products on regulated European exchanges. With regulatory compliance, strategic collaborations with industry leaders and our proficient team, we empower investors on a global level to access innovative and sophisticated investment products that are aligned with the evolving landscape of the global crypto market.

Cryptocurrency investments are associated with high risk. Virtune does not provide investment advice. Investments are made at your own risk. Securities may increase or decrease in value, and there is no guarantee that you will recover your invested capital. Please read the prospectus, KID, terms at www.virtune.com.

BRISBANE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, from October 22 to 25. The final efficacy analysis of the ORIGIN 3 trial of TRUTAKNA in IgA nephropathy (IgAN) will be a featured late-breaking oral presentation during the opening plenary session and also a late-breaking research poster. In addition, interim results from the adult IgAN and primary membranous nephropathy (pMN) cohorts in PIONEER, a Phase 2 basket trial of atacicept in multiple glomerular diseases, will be a late-breaking research oral presentation. In total, five Vera sponsored abstracts will be presented at ASN Kidney Week 2026, demonstrating the Company’s commitment to transforming medicine in autoimmune kidney disease.

Vera Therapeutics Abstract Presentations at ASN Kidney Week 2026
Oral Presentations
Title	The ORIGIN 3 Trial of Atacicept in IgA Nephropathy
Presenting Author	Jonathan Barratt, PhD, FRCP, Mayer Professor of Renal Medicine, University of Leicester
Abstract Number	TH-OR109
Session Title	Opening Plenary
Session Date, Time	Thursday, October 22, 8:00–9:30 AM MDT
Presentation Time	9:05–9:12 AM MDT
Location	Bluebird Ballroom, Convention Center
Supplementary Poster Session	Late-Breaking Research Posters, Thursday, October 22
Poster Board	TH-PO1257
Title	Interim Results from the Adult IgAN and Primary Membranous Nephropathy (pMN) Cohorts in the Atacicept PIONEER Trial
Presenting Author	Richard Lafayette, MD, FACP, Professor of Medicine (Nephrology) and Director of the Glomerular Disease Center at Stanford University Medical Center
Abstract Number	SA-OR079
Session Title	Late-Breaking Research Orals: Pediatrics, Genetics, and Glomerular Diseases
Session Date, Time	Saturday, October 24, 4:30–6:00 PM MDT
Presentation Time	5:30–5:40 PM MDT
Location	Four Seasons Ballroom 2, Convention Center
Poster Presentations
Title	The PIONEER Trial: Expanding Evaluation of Atacicept, a B-Cell-Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL) Inhibitor, to Pediatric Patients with IgAN
Presenting Author	Howard Trachtman, MD, University of Michigan
Session Date, Time	Saturday, October 24, 10:00 AM–12:00 PM MDT
Location	Exhibit Hall, Convention Center
Poster Board	INFO20-SA
Title	Rapid Progression in IgAN Despite Treatment: Real-World Evidence of Suboptimal Disease Control in the United States
Presenting Author	Damemarie Paul, DrPH, MPH, Vera Therapeutics
Session	Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research – Other [PO1402-07]
Session Date, Time	Saturday, October 24, 10:00 AM–12:00 PM MDT
Location	Exhibit Hall, Convention Center
Poster Board	SA-PO0627
Title	Aurora: A Multi-Site Clinical Implementation Network for IgA Nephropathy
Presenting Author	Navdeep Tangri, MD, University of Manitoba
Session Date, Time	Saturday, October 24, 10:00 AM–12:00 PM MDT
Location	Exhibit Hall, Convention Center
Poster Board	INFO19-SA

TRUTAKNA (atacicept-vymj) Indication

TRUTAKNA (atacicept-vymj) is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk for disease progression.

This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether TRUTAKNA slows kidney function decline over the long-term in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

Important Safety Information

Contraindications: TRUTAKNA is contraindicated in patients with serious hypersensitivity to atacicept-vymj or any excipients of TRUTAKNA.

Warnings and Precautions

Immunosuppression and Increased Risk of Infections: TRUTAKNA suppresses the immune system by reducing antibody production, which may increase the risk of infections. Patients with chronic infection or recurring infections may have an increased risk of serious infection. In clinical trials, infections were reported in 32% of TRUTAKNA patients compared with 28% of placebo patients.

Before initiating TRUTAKNA, assess patients for active infections. Delay TRUTAKNA administration in patients with active infection until the infection resolves or is adequately treated. Monitor patients for signs and symptoms of infection during treatment with TRUTAKNA. If a serious infection develops, consider interrupting TRUTAKNA until the infection is controlled.

The concomitant use of TRUTAKNA and other immune-modulating therapies has not been evaluated. Concomitant use of TRUTAKNA with drugs that affect the immune system, including systemic corticosteroids, may increase the risk of infection.

Immunosuppression and Immunization Risk: TRUTAKNA may interfere with the immune response to vaccines and increase the risk of infection from live vaccines. Prior to initiating treatment with TRUTAKNA, complete all age-appropriate immunizations. Live vaccines are not recommended within 30 days prior to initiation or during treatment with TRUTAKNA as safety of coadministration has not been established.

Adverse Reactions: The most common adverse reactions (≥5%) in patients treated with TRUTAKNA and placebo, respectively, were infections (32% vs 28%) and local administration reactions (30% vs 5%). The most common infection was upper respiratory tract infection (12% vs 9%), and the most common local administration reactions were injection site reaction (19% vs 2%) and injection site erythema (6% vs 1%).

Use in Specific Populations

Pregnancy: Available data on TRUTAKNA used in pregnant women exposed during clinical trials are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.

Based on the mechanism of action, TRUTAKNA may cause immunosuppression in the in utero-exposed infant. Consider the potential clinical impact of TRUTAKNA exposure in infants exposed in utero. Pregnant women exposed to TRUTAKNA, or their healthcare provider, should report TRUTAKNA exposure by calling 1-833-633-8372.

Pediatric Use: The safety and effectiveness of TRUTAKNA in pediatric patients have not been established.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Vera Therapeutics at 1-833-MED-VERA or medinfo@veratx.com.

Please see full Prescribing Information for additional Important Safety Information.

About TRUTAKNA

TRUTAKNA, a B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL) inhibitor, is a soluble recombinant fusion protein containing the human transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI) receptor that binds to the cytokines BAFF and APRIL.¹ BAFF and APRIL are key cytokines that activate B cells and drive IgAN pathophysiology. In IgAN, activated B cells produce both the antigen and associated antibodies that result in the production of damaging IgA immune complexes. The overlapping roles of BAFF and APRIL in activating B cells support the potential for TRUTAKNA as a disease-modifying therapy.² TRUTAKNA is self-administered as an at-home, small-volume (1 ml), 150 mg once-weekly autoinjector.

TRUTAKNA TRU SUPPORT™ Patient Support Program

We are dedicated to ensuring that eligible IgAN patients can access the first approved therapy that targets both BAFF and APRIL. TRUTAKNA TRU SUPPORT, our patient support program, offers insurance coverage assistance, financial assistance options for eligible patients, and educational resources designed to support patient access and care. Eligible commercially insured patients may pay as little as $0 out of pocket through our copay assistance program. More information will be available on www.veratx.com.

About IgAN

IgAN is a serious, progressive, immune-mediated kidney disease and a leading cause of chronic kidney disease and kidney failure worldwide.^3,4 Approximately 2.5 adults per 100,000 worldwide are diagnosed with IgAN each year, most often between 30 and 40 years of age.^5,6 Over time, IgAN can lead to irreversible kidney damage and may ultimately require dialysis or kidney transplantation. At least 50% of patients may progress to kidney failure or death within 10 to 20 years of diagnosis.³

About Vera Therapeutics

Vera Therapeutics is a commercial-stage biotechnology company focused on the pursuit of truth in science to transform medicine in autoimmune disease, starting with the kidney. Vera Therapeutics’ flagship commercial product is TRUTAKNA (atacicept-vymj), a BAFF and APRIL inhibitor indicated to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies through inhibition of BAFF and APRIL may prove clinically meaningful. Vera Therapeutics was founded in 2016 and is based in Brisbane, California. To learn more, visit www.veratx.com.

Forward-looking Statements

Statements contained in this press release regarding matters, events or results that may occur in the future are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the potential for TRUTAKNA as a disease-modifying therapy; Vera Therapeutics’ commitment to transforming medicine in autoimmune kidney disease; and the plans, commitments, aspirations and goals under the caption “About Vera Therapeutics”. Words such as “anticipate,” “believe,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Vera Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks related to the regulatory approval process, risks related to commercial launch, market acceptance, and payer coverage, results of earlier clinical trials may not be obtained in later clinical trials, preliminary results may not be predictive of topline results, risks and uncertainties associated with Vera Therapeutics’ business in general, the impact of macroeconomic and geopolitical events, and the other risks described in Vera Therapeutics’ filings with the U.S. Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Vera Therapeutics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

References

1. TRUTAKNA™ [Prescribing Information]. Brisbane, CA: Vera Therapeutics, Inc; July 2026

2. Cheung CK, Barratt J, Liew A, Zhang H, Tesar V, Lafayette R. The role of BAFF and APRIL in IgA nephropathy: pathogenic mechanisms and targeted therapies. Front Nephrol. 2024;3:1346769. Published 2024 Feb 1. doi:10.3389/fneph.2023.1346769

3. Pitcher D, Braddon F, Hendry B, et al. Long-Term Outcomes in IgA Nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727-738. doi:10.2215/CJN.0000000000000135

4. McGrogan A, Franssen CF, de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant. 2011;26(2):414-430. doi:10.1093/ndt/gfq665

5. Jarrick S, Lundberg S, Welander A, et al. Mortality in IgA Nephropathy: A Nationwide Population-Based Cohort Study. J Am Soc Nephrol. 2019;30(5):866-876. doi:10.1681/ASN.2018101017

For more information, please contact:
Investor Contact:
Joshua Qin
Vera Therapeutics
650-360-6978
ir@veratx.com

Media Contact:
Debra Charlesworth
Vera Therapeutics
415-854-8051
corporatecommunications@veratx.com

YANTAI, China, Oct. 02, 2026 (GLOBE NEWSWIRE) — Decent Holding Inc. (NASDAQ: DXST) (the “Company”), a technology-driven provider of wastewater treatment and community-based senior health and elderly care services in China today announced that it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an institutional investor for the sale of (i) in a registered direct offering, 822,828 Class A ordinary shares, par value of $0.0025 per share, of the Company (the “Class A Ordinary Shares”) or, in lieu thereof, pre-funded warrants, at a purchase price of $1.50 per share; and (ii) in a concurrent private placement, unregistered warrants (the “Unregistered Warrants”) to purchase up to 822,828 Class A Ordinary Shares, with an exercise price of $1.50 per share (together, the “Securities”).

The gross proceeds from the offering of the Class A Ordinary Shares (or pre-funded warrants in lieu thereof) are expected to be approximately $1.23 million, before deducting placement agent fees and other offering expenses.

The offering is expected to close on or about October 5, 2026, subject to the satisfaction of customary closing conditions.

The Company expects to use the net proceeds from this offering for working capital and general corporate purposes.

FT Global Capital, Inc. is acting as the exclusive placement agent for the offering.

The offering of the Class A Ordinary Shares (or pre-funded warrants in lieu thereof) is being made pursuant to the Company’s “shelf” registration statement on Form F-3 (File No. 333-295313), which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 24, 2026, and declared effective on May 7, 2026. A prospectus supplement and the accompanying prospectus relating to the Class A Ordinary Shares (or pre-funded warrants in lieu thereof) will be filed with the SEC and will be available on the SEC’s website at www.sec.gov.

The Unregistered Warrants were issued in a concurrent private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Regulation D promulgated thereunder and, along with the Class A ordinary shares underlying the warrants, have not been registered under the Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying Class A ordinary shares may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Decent Holding Inc.

Decent Holding Inc. (NASDAQ: DXST) specializes in the provision of wastewater treatment by cleansing industrial wastewater, ecological river restoration and river ecosystem management by enhancing water quality, as well as microbial products primarily used for pollutant removal and water quality enhancement, through the Company’s operating subsidiary, Shandong Dingxin Ecology Environmental Co., Ltd. In addition, through its operating subsidiary Suncare (Shanghai) Health Technology Co., Ltd., the Company operates an AI-powered, community-based senior health and elderly care platform serving China’s aging population. For more information, please visit the Company’s website.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “plan,” “should,” “could,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “potential”, or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect subsequent events or circumstances, except as required by applicable law.

Investor Relations Contact:

WFS Investor Relations Inc.
Connie Kang, Partner
Email: ckang@wfsir.com
Tel: +86 1381 185 7742

• Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-up
• Poster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile across immune-mediated diseases
• Poster presentation characterizing the high unmet medical need and low clinical response rates among patients with refractory RA following an inadequate response to at least two distinct classes of biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), a population similar to that being studied in the Phase 3 registrational trial
• Live webcast on Monday, November 9, 2026 at 8:15 am EST to review Artiva’s presentations, including an in-depth analysis of data from at least 10 patients with refractory RA who have at least six months of follow-up and would meet key eligibility criteria for the Phase 3 registrational trial

SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced one oral and two poster presentations at ACR Convergence 2026 featuring updated data from its AlloNK^® program and a registry analysis of the high unmet medical need in refractory RA.

Artiva will host a live webcast on Monday, November 9, 2026, at 8:15 am EST to review its ACR presentations and updated clinical data from at least 20 patients with refractory RA who have at least six months of follow-up. The webcast will include an in-depth analysis of data from at least 10 of these patients who would meet key eligibility criteria for the Phase 3 registrational trial.

The following abstracts will be presented at ACR Convergence 2026, taking place November 6 – 11, 2026, at the Orange County Convention Center in Orlando:

1899 Oral Presentation	AB-101, Outpatient-Administered, Non-Genetically Modified NK Cells in Combination with Rituximab Generate Robust Efficacy Responses Comparable with Autologous CAR T in 34 Patients with Rheumatologic Diseases
Presenting Author:	Guillermo J. Valenzuela, M.D., F.A.C.R. Medical Director, Integral Rheumatology & Immunology Specialists
Session:	Abstracts: Rheumatoid Arthritis – Treatment
Date/Time/Location:	Monday, November 9, 2026 at 3:00 – 4:30 pm EST
2384 Poster	AB-101, Outpatient-Administered, Non-Genetically Modified NK Cells in Combination with Rituximab, Demonstrates Favorable Safety Profile in a Large Cohort of 60 Patients with Rheumatological Diseases while Consistently Achieving Deep B-cell Depletion
Presenting Author:	Subhashis Banerjee, M.D. Chief Medical Officer, Artiva Biotherapeutics
Session:	Poster Session C: Rheumatoid Arthritis – Treatment
Date/Time/Location:	Tuesday, November 10, 2026 at 10:30 am – 12:30 pm EST, WB1 & 2
2402 Poster	High Unmet Need and Low Clinical Response Rates Among Rheumatoid Arthritis Patients Failing Two or More Classes of b/tsDMARDs: A United States Registry Analysis
Presenting Author:	Jonathan Kay, M.D., M.A.C.R. Timothy S. and Elaine L. Peterson Chair in Rheumatology, UMass Chan Medical School
Session:	Poster Session C: Rheumatoid Arthritis – Treatment
Date/Time/Location:	Tuesday, November 10, 2026 at 10:30 am – 12:30 pm EST, WB1 & 2

For more information on these and other abstracts, please visit the ACR Convergence 2026 website.

Virtual Webcast Details
Investors and the general public are invited to register for the webcast here. A live question-and-answer session will follow the presentation. A replay will be available for 90 days in the Investors section of Artiva’s website.

About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases. Artiva is initiating a Phase 3 registrational trial of its lead program, AlloNK^® (also known as AB-101), for refractory rheumatoid arthritis (RA) during the second half of 2026. AlloNK is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved natural killer (NK) cell therapy candidate designed to enhance antibody-dependent cellular cytotoxicity in combination with a range of therapeutic antibodies. Initial clinical data evaluating AlloNK in combination with anti-CD20 antibodies have demonstrated encouraging activity across multiple B-cell-driven autoimmune diseases and a tolerability profile supportive of outpatient administration. Artiva is developing AlloNK plus rituximab as a scalable, outpatient-administered, deep B-cell depletion treatment regimen for use in community rheumatology settings. In addition to refractory RA, AlloNK is being evaluated in Sjögren disease, systemic sclerosis and myositis.

Artiva is headquartered in San Diego, California. For more information, please visit www.artivabio.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: the potential benefits, accessibility, practicality, effectiveness, safety and tolerability of AlloNK, including based on interim pooled data across clinical trials, and the potential for administration in an outpatient community setting; the registrational Phase 3 trial for AlloNK, including trial design, expectations for response rates, and timing of initiation, future updates on site activation and enrollment, and topline data readout; and Artiva’s ability to generate sufficient data to support a BLA submission; clinical data expected to be presented from patients with refractory RA, SjD and SSc, and the timing of such data disclosures; the number of patients with data from the basket study who would be expected to meet the key eligibility criteria for the planned Phase 3 trial; Artiva’s ability to realize the potential benefits associated with FDA RMAT designation for AlloNK; Artiva’s beliefs regarding its competitive position, including its belief that AlloNK may be the first deep B-cell depleting therapy of any modality to reach patients with, and be approved and commercialized in, refractory RA; and Artiva’s future results of operations and financial position, including cash runway. These forward-looking statements are based on the beliefs of the management of Artiva as well as assumptions made by and information currently available to Artiva. Such statements reflect the current views of Artiva with respect to future events and are subject to known and unknown risks and uncertainties, including, without limitation, risks and delays relating to initiation of the Phase 3 registrational trial, activation of clinical trial sites, patient enrollment and the availability and timing of disclosure of data; risks that future clinical trial results may not be consistent with interim, initial, preliminary, or topline results or results from prior preclinical studies or clinical trials, or with Artiva’s expectations; the risk that the number of patients, or the duration of follow-up for such patients, available for presentation differs from current expectations; the risk that differences exist between trial designs, patient characteristics and other factors for the Phase 3 trial, Artiva-sponsored Phase 2a basket trial and investigator-initiated basket trial, and caution should be exercised in drawing any conclusions from such data across separate trials as such pooling and comparative data is inherently limited and such data may not be directly comparable; the risk that other deep B-cell depleting therapies may advance more rapidly than Artiva currently anticipates, that Artiva’s assessment of publicly disclosed competitor development timelines may be incomplete or inaccurate, and that Artiva may not achieve or be the first to achieve regulatory approval or commercialization of a therapy in this category; the risk that Artiva’s registrational strategy is based in part on recent interactions with the FDA and later feedback from the FDA may be inconsistent with past interactions; Artiva’s ability to obtain adequate financing to fund its planned clinical trials and other expenses; risks inherent in developing product candidates; and risks related to the legal and regulatory framework for the industry. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause Artiva’s actual results to differ from current expectations are discussed in Artiva’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in Artiva’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, Artiva undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts

Investors & Media
Noopur Batsha Liffick, MPH
NBL LifeSci Advisory LLC
ir@artivabio.com

Source: Artiva Biotherapeutics, Inc.

AB “Ignitis grupė” (hereinafter – the Group) announces that Kepler Cheuvreux, a leading independent European financial services company, with a strong presence in equity research and brokerage, has initiated sponsored research of the Group’s stock and published the initiation report.

Its research includes insights on the Group’s performance, potential, estimates and valuation. The initiation report and subsequent updates will be publicly available on Kepler Cheuvreux Research Hub here.

“We welcome Kepler Cheuvreux’s initiation of equity research coverage of Ignitis Group. As Europe’s leading independent equity broker, Kepler Cheuvreux brings an additional independent perspective on our performance, strategy and long-term value creation. Its analysis will further strengthen our visibility and engagement across the capital markets,” says Jonas Rimavičius, CFO and member of the Management Board of Ignitis Group.

The recommendations and consensus of equity research analysts covering the Group’s stock is available here.

Legal notice:
The research is prepared by Kepler Cheuvreux under a sponsored research arrangement and reflects the independent views of its authors. The reports are prepared based on publicly available information, provided for information purposes only and does not constitute investment advice or a recommendation to buy, sell or hold securities. The Group assumes no responsibility for the analyses, opinions or conclusions contained in the report. Any investment decision remains solely the responsibility of the investor.

For additional information, please contact:

Communications
Valdas Lopeta
+370 621 77993
valdas.lopeta@ignitis.lt 

Investor Relations
Ainė Riffel-Grinkevičienė
+370 643 14925
aine.riffel-grinkeviciene@ignitis.lt

• New immune data from the phase 2 trial with EVX-01 to be presented both in an oral and poster presentation
• New data follows from the three-year clinical update for EVX-01 to be provided at the European Society for Medical Oncology (ESMO) 2026 congress on October 24, 2026

COPENHAGEN, Denmark, October 2, 2026 – Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology™ platform, will present new immune data for AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, taking place in Phoenix, Arizona, November 4-8, 2026.

The new data will reflect the systemic immunomodulatory effects of EVX-01 plus pembrolizumab beyond vaccine-specific T-cell responses using comprehensive immune profiling. It will be presented both in an oral and poster presentation at the SITC meeting.

The new immune data stems from the phase 2 trial investigating EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced melanoma. Each patient enrolled in the trial received a unique vaccine designed and manufactured based on their individual biology. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

The complete three-year clinical data from the phase 2 trial will be presented at the European Society for Medical Oncology (ESMO) 2026 congress on October 24, 2026. Two-year data demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. Additionally, a durable clinical benefit was observed as 92% of patients were still responding at two years follow-up and no relapses were observed.

In the third year, patients received EVX-01 as stand-alone therapy, meaning the data will offer insight into the vaccine’s effect also when not administered in combination with anti-PD-1 therapy. Further, the data may also provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response.

SITC oral and poster presentation details:

• Abstract title: EVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanoma
• Abstract#: 502

Oral presentation:

• Session: 105b: Rapid Oral – Clinical 1
• Location: Phoenix Convention Center, West Building-300 Level – 301BC
• Date/Time: Friday, November 6, 2026, 12:30-1:30pm MT / 20:30-21:30 CET       
• Presenter: Mads Lausen, Senior Scientist at Evaxion

Poster presentation:

• Session: Poster Session
• Location: Phoenix Convention Center, North Building-Lower Level – Exhibition Halls 4-6
• Date/Time: Saturday, November 7, 2026, 12:30-1:30pm & 6:40-8:10pm MT / 20:30-21:30 CET & 02:40-04:10 CET (Sunday, November 8)
• Presenter: Mads Lausen, Senior Scientist at Evaxion

About EVX-01
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors. It is currently being evaluated as a treatment of advanced melanoma and is Evaxion’s lead clinical asset.

Designed with our AI-Immunology™ platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system to fight off cancer by mounting a targeted response against tumor-specific neoantigens.

In the phase 2 trial in patients with advanced melanoma (skin cancer), EVX-01 has demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. 86% of the EVX-01 neoantigen targets triggered a tumor-specific immune response in the patients.

Contact information 
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai

About Evaxion
Evaxion is a pioneering clinical-stage TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer as well as infectious and autoimmune diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development.

We have developed a pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients’ lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website. 

Forward-looking statement 
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law. 

As automated exploits dismantle traditional defense models in hours, Rapid7 unites threat intelligence, vulnerability research, and Rapid7 Labs to end reactive cybersecurity once and for all

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) — Today, Rapid7, Inc. (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, announced the launch of Rapid7 Intelligence, a unified engine designed to transform enterprise threat defenses from reactive monitoring to proactive prevention. By combining threat intelligence, vulnerability research, and the legacy of Rapid7 Labs, Rapid7 Intelligence transforms insights on attacker behavior into AI-powered action to help organizations anticipate and disrupt attacks.

Indicators Expire. Behavior Doesn’t: Defense for the Agentic Era.
Building on Rapid7 Labs’ 13-year legacy, Rapid7 Intelligence turns attacker behavior into scalable protection faster than traditional vendors reliant on static indicators. With AI compressing exploitation windows to minutes—and 8,539 critical vulnerabilities tracked in Q2 alone—attackers are leveraging automation to scale phishing, reconnaissance, and script development. Rapid7 Intelligence monitors these threats in real time to deliver actionable, expert-validated insights that keep defenders ahead.

“Static threat intelligence isn’t completely dead—it’s just sitting in standard dashboards doing what it’s always done, giving organizations a false sense of security while autonomous threat agents burn down their perimeters,” said Christiaan Beek, Vice President of Rapid7 Intelligence. “The real differentiator isn’t hoarding more raw feeds; it’s having curated, vetted intelligence focused relentlessly on true signals rather than waiting around for alerts to trigger after the damage is done. Rapid7 Intelligence isn’t built to generate another 50-page PDF report for security teams to ignore; it aggressively converts real-time operational adversary insight into a proactive, preemptive shield.”

Rapid7 Intelligence in Action: Behavioral Correlation Exposes a Hidden Linux Malware Ecosystem
A concrete illustration of Rapid7 Intelligence’s power is a new finding from Rapid7 researchers, who uncovered a modular Linux malware ecosystem—spanning new BPFDoor variants, BPF Rekoobe, droppers, and AVERAT implants—actively targeting telecom and network-edge devices.

Researchers identified two campaigns linked by a common focus on the network edge. Rapid7 Intelligence analyzed their shared behaviors, uncovering an emerging pattern: using SMTP to blend into the victim’s DMZ, target mail security appliances, and maintain long-term access.

New BPFDoor variants indicate the malware family is evolving into an ecosystem where each sample is tailored to the telco plane (control, management, and data plane) it targets, and where threat actors know exactly what software is adopted at each layer.

Rapid7 Intelligence will continue tracking and disrupting tactics like this to keep defenders ahead of attackers.

Expert-Led, Actionable Intelligence
To continuously power research like this and help defenders stay ahead of emerging threats, Rapid7 Intelligence delivers:

• Immediate Protective Force: Frontline intelligence bypasses legacy research lags, flowing directly into Rapid7 products, MDR, and Exposure Management to neutralize adversary infrastructure before attacks execute.
• Unified Intelligence Engine: Threat intelligence, vulnerability analysis, and engineering inside the products customers already run, instead of a report they have to translate into action themselves.
• Uncompromised Community Arsenal: Building on the legendary foundation of Metasploit and Rapid7 Labs, critical advisories, vulnerability research and exploitation insights remain open, ensuring the industry stays capable of pushing back.

“In a world of infinite telemetry and automated attacks, playing defense with traditional tools is an exercise in futility,” said Mel Stone, Chief Global Services Officer at Rapid7. “Rapid7 Intelligence shifts the balance of power. By fusing machine-scale observation with frontline human expertise, we turn raw threat data into immediate, actionable intelligence—empowering security teams to disrupt adversaries before they establish a foothold.”

To learn more about Rapid7 Intelligence, visit here.

About Rapid7
Rapid7, Inc. (NASDAQ: RPD) is a global leader in AI-powered managed cybersecurity operations, trusted to advance organizations’ cyber resilience. Open and extensible, the Rapid7 Command Platform integrates security data, enriching it with AI, threat intelligence, and 25 years of expertise and innovation to reduce risk and disrupt attackers. As a recognized leader in preemptive managed detection and response (MDR), Rapid7 unifies exposure and detection to transform the cybersecurity operations of more than 11,500 customers worldwide. For more information, visit our website, check out our blog, or follow us on LinkedIn or X.

Media Contact
Christine Nurnberger
SVP Global Marketing and Growth
press@rapid7.com

Rapid7 Investor Contact
Christopher Keenan
Vice President, Deputy General Counsel
investors@rapid7.com

SUNNYVALE, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) —

News Summary
Fortinet® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, announced that it will hold a conference call to discuss its third quarter 2026 financial results on Wednesday, October 28, at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

Fortinet’s financial results conference call will be broadcast live in listen-only mode on the company’s investor relations website at http://investor.fortinet.com. While not required, it is recommended that you join at least 10 minutes prior to the event start.

The CEO’s and CFO’s prepared remarks, supplemental slides, and a call replay will be accessible from the Quarterly Earnings page on the Investor Relations page of Fortinet’s website at https://investor.fortinet.com/quarterly-earnings.

About Fortinet
Fortinet (Nasdaq: FTNT) is a driving force in the evolution of cybersecurity and the convergence of networking and security. Our mission is to secure people, devices, and data everywhere, and today we deliver cybersecurity everywhere our customers need it with the largest integrated portfolio of over 50 enterprise-grade products. Over a million lifetime customers trust Fortinet’s solutions, which are among the most deployed, most patented, and most validated in the industry. The Fortinet Training Institute, one of the largest and broadest training programs in the industry, is dedicated to making cybersecurity training and new career opportunities available to everyone. Collaboration with esteemed organizations from both the public and private sectors, including Computer Emergency Response Teams (CERTS), government entities, and academia, is a fundamental aspect of Fortinet’s commitment to enhance cyber resilience globally. FortiGuard Labs, Fortinet’s elite threat intelligence and research organization, develops and utilizes leading-edge machine learning and AI technologies to provide customers with timely and consistently top-rated protection and actionable threat intelligence. Learn more at https://www.fortinet.com and https://www.fortinet.com/blog.

FTNT-F

Copyright © 2026 Fortinet, Inc. All rights reserved. The symbols ® and ™ denote respectively federally registered trademarks and common law trademarks of Fortinet, Inc., its subsidiaries and affiliates. Fortinet’s trademarks include, but are not limited to, the following: Fortinet, the Fortinet logo, FortiGate, FortiOS, FortiGuard, FortiCare, FortiAnalyzer, FortiManager, FortiASIC, FortiClient, FortiCloud, FortiCore, FortiMail, FortiSandbox, FortiADC, FortiAgent, FortiAI, FortiAIOps, FortiAntenna, FortiAP, FortiAPCam, FortiAppSec, FortiAuthenticator, FortiBranchSASE, FortiCall, FortiCam, FortiCamera, FortiCarrier, FortiCART, FortiCASB, FortiCentral, FortiConnect, FortiController, FortiConverter, FortiDAST, FortiDATA, FortiDB, FortiDevice, FortiDDoS, FortiDeceptor, FortiDeploy, FortiDevice, FortiDevSec, FortiDLP, FortiEdge, FortiEDR, FortiEndpoint, FortiExplorer, FortiExtender, FortiFirewall, FortiFlex, FortiFone, FortiGSLB, FortiGuest, FortiHSM, FortiHypervisor, FortiIdentity, FortiInsight, FortiIsolator, FortiLink, FortiMonitor, FortiNAC, FortiNDR, FortiPAM, FortiPhish, FortiPoint, FortiPoints, FortiPortal, FortiPresence, FortiProxy, FortiRecon, FortiRecorder, FortiSASE, FortiSAT, FortiSEC, FortiSIEM, FortiSMS, FortiSOAR, FortiSOC, FortiSRA, FortiSwitch, FortiTelemetry, FortiTester, FortiTIP, FortiToken, FortiTrust, FortiVoice, FortiWAN, FortiWeb, FortiWiFi, FortiWLC, FortiWLM, FortiXDR, Lacework FortiCNAPP, Linksys, Intelligent Mesh, Velop, Max-Stream, Performance Perfected, and SECURITY FABRIC.

Other trademarks belong to their respective owners. Fortinet has not independently verified statements or certifications herein attributed to third parties and Fortinet does not independently endorse such statements. Notwithstanding anything to the contrary herein, nothing herein constitutes a warranty, guarantee, contract, binding specification or other binding commitment by Fortinet or any indication of intent related to a binding commitment, and performance and other specification information herein may be unique to certain environments.

Media Contact:	Investor Contact:	Analyst Contact:
Tiffany Curci	Anthony Luscri	Sarah Goodwin
Fortinet, Inc.	Fortinet, Inc.	Fortinet, Inc.
408-235-7700	408-235-7700	408-235-7700
pr@fortinet.com	investors@fortinet.com	sgoodwin@fortinet.com

• Seven abstracts spanning CKD translational model studies and drug product characterization provide converging evidence supporting a multifactorial mechanism of action for rilparencel
• One clinical abstract presents a new pooled Phase 2 analysis of patients meeting key PROACT 1 inclusion criteria that continues to indicate a strong safety profile and kidney function stabilization in patients with advanced CKD and type 2 diabetes mellitus

WINSTON-SALEM, N.C., Oct. 02, 2026 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that the Company will present eight abstracts, including one oral presentation, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held from October 21-25, 2026, in Denver, CO.

“The data being presented at Kidney Week 2026 continue to build a more cohesive picture of how rilparencel may lead to stabilization of kidney function,” said Bruce Culleton, M.D., CEO of ProKidney. “Across multiple complementary non-clinical models, we are seeing evidence supporting an adaptive, multifactorial mechanism that involves attenuation of oxidative damage, metabolic dysregulation, and pro-inflammatory signaling, while supporting vascular and tubular repair within diseased and injured kidney cells. Importantly, these mechanistic observations coupled with the stabilization of kidney function observed across our recent Phase 2 studies in patients with advanced CKD and type 2 diabetes further strengthen our confidence in the ongoing Phase 3 PROACT 1 study.”

The titles for the accepted abstracts are provided below and are accessible online at: https://www.asn-online.org/education/kidneyweek/2026/program-search-abstract.aspx

Oral Presentation Details

Rilparencel Is Associated with a Graft-Adjacent Remodeling Response and Preserved Vascular Integrity in an Immunocompromised Rat CKD Model
Abstract Number: FR-OR044
Session Title: Exciting Developments in CKD Research: From Diagnostics to Management and More
Date, Time: October 23, 2026 from 4:30 PM to 6:00 PM MDT (ProKidney presentation starts at 5:40 PM)
Location: Mile High Ballroom 1D

Poster Presentation Details

A Human Microphysiological System Resolves Epithelial Inflammatory Injury Programs and Characterizes Autologous Cell Therapy Responses in a CKD Injury Model
Session Title: Bioengineering: Emerging Research
Date, Time: October 22, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: TH-PO1128

Long-Duration Air-Liquid Interface Culture of Human CKD Kidney Biopsies Enables Ex Vivo Study of Disease Biology and Tissue-Context-Specific Effects of Kidney-Targeted Therapies
Session Title: Bioengineering: Emerging Research
Date, Time: October 22, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: TH-PO1129

Metabolic Transitioning During Manufacturing of Renal Cell Therapy Candidate Rilparencel
Session Title: CKD: Mechanisms of Injury and Fibrosis – 2
Date, Time: October 23, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: FR-PO0236

Renal Autologous Cell Therapy for CKD with Diabetes: Pooled Safety and Efficacy Results from a Phase 2 Program in a Subset of Participants with Key Phase 3 Eligibility Characteristics
Session Title: CKM: Clinical – Trials, Epidemiology, and Biomarkers
Date, Time: October 23, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: FR-PO0498

GPX4-Associated Cytoprotective Activity of an Autologous Cell Therapy in Human In Vitro and Ex Vivo CKD Models
Session Title: Development, Stem Cells, and Regenerative Medicine
Date, Time: October 24, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: SA-PO0013

Rilparencel Manufacturing Induces Transcriptional Dedifferentiation Leading to Two Distinct Populations with Retained Tubular Lineage Memory
Session Title: Development, Stem Cells, and Regenerative Medicine
Date, Time: October 24, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: SA-PO0014

Longitudinal Secretome Characterization of Renal Cell Therapy Candidate Rilparencel During Manufacturing
Session Title: Development, Stem Cells, and Regenerative Medicine
Date, Time: October 24, 2026 from 10:00 AM to 12:00 PM MDT
Poster Board Number: SA-PO0015

Following the event, a copy of the poster presentations will be available on the Company’s website at: https://prokidney.com/our-technology/publications/

About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead investigational product candidate, rilparencel (also known as REACT^®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. ProKidney’s actual results may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the achievement and timing of the topline data readout of the Company’s PROACT 1 trial and other milestones provided, the Company’s beliefs that its Phase 3 REGEN-006 (PROACT 1) trial could be sufficient to support a potential BLA submission and full regulatory approval, that eGFR slope can be used as a surrogate endpoint on an accelerated approval pathway for rilparencel, expectations with respect to financial results and expected cash runway, including the Company’s expectation that current cash will support operating plans into mid-2027, future performance, development and commercialization of products, if approved, the potential benefits and impact of the Company’s products, if approved, potential regulatory approvals, the size and potential growth of current or future markets for the Company’s products, if approved, the advancement of the Company’s development programs into and through the clinic and the expected timing for reporting data, the making of regulatory filings or achieving other milestones related to the Company’s product candidates, and the advancement and funding of the Company’s developmental programs, generally. Most of these factors are outside of the Company’s control and are difficult to predict. Factors that may cause such differences include, but are not limited to: disruptions to our business or that may otherwise materially harm our results of operations or financial condition as a result of our recent domestication to the United States; the inability to maintain the listing of the Company’s Class A common stock on Nasdaq; the inability of the Company’s Class A common stock to remain included in various indices and the potential negative impact on the trading price of the Class A common stock if excluded from such indices; the inability to implement business plans, forecasts, and other expectations or identify and realize additional opportunities, which may be affected by, among other things, competition and the ability of the Company to grow and manage growth profitably and retain its key employees; the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry; the risk that results of the Company’s clinical trials may not support approval; the risk that the FDA could require additional studies before approving the Company’s drug candidates; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to compete with other companies currently marketing or engaged in the biologics market and in the area of treatment of kidney diseases; the size and growth potential of the markets for the Company’s products, if approved, and its ability to serve those markets, either alone or in partnership with others; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s financial performance; the Company’s intellectual property rights; uncertainties inherent in cell therapy research and development, including the actual time it takes to initiate and complete clinical studies and the timing and content of decisions made by regulatory authorities; the fact that interim results from our clinical programs may not be indicative of future results; the impact of geo-political conflict on the Company’s business; and other risks and uncertainties included under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. The Company cautions readers that the foregoing list of factors is not exclusive and cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

ProKidney Contact
Ethan Holdaway
Ethan.Holdaway@prokidney.com

Media Contact
Audra Friis
audrafriis@sambrown.com

Investor Relations Contact
Daniel Ferry
Daniel@lifesciadvisors.com

NEEDHAM, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present data from its aglatimagene besadenovec program in non-small cell lung cancer (NSCLC) in patients with progressive NSCLC despite immune checkpoint inhibitor (ICI) treatment, as well as clinical and mechanistic findings from its phase 1b clinical trial of linoserpaturev in recurrent glioblastoma, through two accepted poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 41st Annual Meeting, taking place November 4-8, 2026 in Phoenix, Arizona.

Aglatimagene besadenovec – NSCLC

Title: Multi-omics analyses reveal intratumoral and systemic immune activation to aglatimagene besadenovec+valacyclovir related to improved survival in patients with progressive NSCLC despite ICI treatment

Presenter: Caroline Duault, PharmD, PhD, Senior Research Scientist, Stanford University

Abstract Number: 603

Session Date: Friday, November 6, 2026

Location: Phoenix Convention Center – North Building – Lower Level – Exhibition Halls 4, 5 and 6

Linoserpaturev – Recurrent Glioblastoma

Title: Combining linoserpaturev with Vascular Endothelial Growth Factor (VEGF) blockade to overcome hypoxia-associated immune suppression in glioblastoma

Presenter: Francesca Barone, MD, PhD, Chief Scientific Officer, Candel Therapeutics

Abstract Number: 468

Session Date: Saturday, November 7, 2026

Location: Phoenix Convention Center – North Building – Lower Level – Exhibition Halls 4, 5 and 6

About aglatimagene besadenovec

Aglatimagene besadenovec (aglatimagene), Candel’s most advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus designed to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s tumor. After intratumoral administration, HSV-tk enzyme activity results in conversion of prodrug (valacyclovir) into deoxyribonucleic acid (DNA)-incorporating nucleotide analogs, leading to immunogenic cell death in cells exhibiting DNA damage and proliferating cells, with subsequent release of a variety of tumor (neo)antigens in the tumor microenvironment. At the same time, the adenoviral serotype 5 capsid proteins promote inflammation through the induction of expression of pro-inflammatory cytokines, chemokines, and adhesion molecules. Together, this regimen is designed to induce an individualized and specific CD8+ T cell-mediated response against the injected tumor and uninjected distant metastases for broad anti-tumor activity, based on in situ immunization against a variety of tumor antigens. Aglatimagene has the potential to treat a broad range of solid tumors. Encouraging monotherapy activity as well as combination activity with standard of care radiotherapy, surgery, chemotherapy, and immune checkpoint inhibitors have previously been shown in several nonclinical and clinical settings. More than 1,000 patients have been dosed with aglatimagene in clinical trials with a favorable tolerability profile to date, supporting the potential for use with standard of care, when indicated. Aglatimagene is currently not approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any use.

About linoserpaturev

Linoserpaturev is a first-in-class, replication-competent, next-generation oncolytic herpes simplex virus-1 (HSV-1) immunotherapy candidate designed for dual activity for oncolysis and immune activation in a single therapeutic. In October 2023, the Company announced that Nature published results from the ongoing clinical trial where linoserpaturev was reported to be generally well-tolerated with no dose-limiting toxicity. In the clinical trial, the investigators observed improved median overall survival compared to historical controls after a single linoserpaturev injection in this therapy-resistant condition¹. The Company and academic collaborators are currently supported by Break Through Cancer to evaluate the effects of repeated linoserpaturev injections in patients with recurrent glioblastoma in an expansion cohort from the phase 1b clinical trial. In October 2025, an original manuscript, published in Science Translational Medicine reported collected findings from a comprehensive analysis of 97 serial tumor biopsies collected from two patients treated with repeated administrations of linoserpaturev in arm C. Linoserpaturev previously received Fast Track Designation and Orphan Drug Designation for the treatment of recurrent high-grade glioma (rHGG) from the FDA.

About Candel Therapeutics

Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (aglatimagene) is the lead product candidate from the adenovirus platform. The Company completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the FDA and published in The Lancet Oncology. The FDA also granted Fast Track Designation and Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate- to high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.

Linoserpaturev is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in rHGG. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.

For more information about Candel, visit: www.candeltx.com.

Forward-Looking Statements

This press release includes certain disclosures that contain “forward-looking statements,” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, express or implied statements regarding the timing and advancement of current and future development programs; expectations regarding the therapeutic benefit of the Company’s platforms, including the ability of its platforms to improve overall survival and/or disease-free survival of patients living with difficult-to-treat, solid tumors; and expectations regarding the potential benefits conferred by regulatory designations. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of development programs; expectations regarding the therapeutic benefit of the Company’s programs; that final data from the Company’s nonclinical studies and completed clinical trials may differ materially from reported interim data from ongoing studies and trials; the Company’s ability to efficiently discover and develop product candidates; the Company’s ability to obtain and maintain regulatory approval of product candidates; the Company’s ability to maintain its intellectual property; the implementation of the Company’s business model, including strategic plans for the Company’s business and product candidates; the impact of the Company’s existing and any future indebtedness on its ability to operate its business; the Company’s ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder; and other risks identified in the Company’s filings with the U.S. Securities and Exchange Commission (SEC), including the Company’s most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q, each as filed with the SEC and any subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent the Company’s views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date.

Investor Contact
Theodore Jenkins
Vice President, Investor Relations, and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com

Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com